Research ArticleEmerging Therapies: Drugs and Regimens
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C. Bain, Serge Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde
DOI: 10.2337/dc18-0623 Published 1 September 2018
Chantal Mathieu
1Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium
Paresh Dandona
2Department of Medicine, State University of New York at Buffalo, Buffalo, NY
Pieter Gillard
1Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium
Peter Senior
3Division of Endocrinology, University of Alberta, Edmonton, Canada
Christoph Hasslacher
4Diabetesinstitut Heidelberg, Heidelberg, Germany
Eiichi Araki
5Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Marcus Lind
6Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
7Department of Medicine, NU Hospital Group, Uddevalla, Sweden
Stephen C. Bain
8Diabetes Research Unit, Swansea University, Swansea, Wales, U.K.
Serge Jabbour
9Division of Endocrinology, Diabetes and Metabolic Diseases, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Niki Arya
10AstraZeneca, Gaithersburg, MD
Lars Hansen
11MedImmune, Gaithersburg, MD
Fredrik Thorén
12AstraZeneca, Gothenburg, Sweden
Anna Maria Langkilde
12AstraZeneca, Gothenburg, Sweden